These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3447424)

  • 1. Separation of peptidic inhibitor of erythropoiesis in uremia.
    Saito A; Ogawa H; Chung TG; Hotta T
    Adv Exp Med Biol; 1987; 223():111-4. PubMed ID: 3447424
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anemia of chronic renal failure: erythropoiesis and serum inhibitor(s) of erythroid progenitor cells in uremia].
    Urushiyama M; Moriyama Y
    Rinsho Ketsueki; 1985 May; 26(5):668-73. PubMed ID: 4057581
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of uremic toxins in exacerbating anemia in renal failure.
    Macdougall IC
    Kidney Int Suppl; 2001 Feb; 78():S67-72. PubMed ID: 11168986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heme synthesis in anemia of the uremic state.
    Linkesch W; Stummvoll HK; Wolf A; Müller M
    Isr J Med Sci; 1978 Nov; 14(11):1173-6. PubMed ID: 750546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical definition of uremia].
    Ringoir S
    Verh K Acad Geneeskd Belg; 1981; 43(2):105-19. PubMed ID: 7314875
    [No Abstract]   [Full Text] [Related]  

  • 6. [Regression of uremia-induced suppression of erythropoiesis in patients with chronic kidney disease].
    Uhl N; Rehn K
    Verh Dtsch Ges Inn Med; 1974; 80():755-7. PubMed ID: 4454655
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythropoiesis.
    Galli F; Beninati S; Benedetti S; Lentini A; Canestrari F; Tabilio A; Buoncristiani U
    Kidney Int Suppl; 2001 Feb; 78():S73-6. PubMed ID: 11168987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GIP and DIP: a new view of uraemic toxicity.
    Haag-Weber M; Mai B; Cohen G; Hörl WH
    Nephrol Dial Transplant; 1994; 9(4):346-7. PubMed ID: 8084443
    [No Abstract]   [Full Text] [Related]  

  • 9. Ferrokinetics in patients on CAPD: influence of CAPD on the anemia of uremia.
    Lee HB; Koh SW; Park HS
    Korean J Intern Med; 1986 Jan; 1(1):54-9. PubMed ID: 15759377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current aspects of the pathogenesis and therapy of anemia in chronic kidney failure].
    Kirov Ch; Koĭchev A
    Vutr Boles; 1989; 28(6):13-6. PubMed ID: 2699126
    [No Abstract]   [Full Text] [Related]  

  • 11. A defense of the middle molecule hypothesis.
    Funck-Brentano JL; Cueille GF; Man NK
    Kidney Int Suppl; 1978 Jun; (8):S31-5. PubMed ID: 278894
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anemia in patients with chronic kidney failure undergoing systematic hemodialysis treatment].
    Landar' VA; Sarycheva TG; Shemetov VD; Kozinets GI
    Urol Nefrol (Mosk); 1989; (1):54-5. PubMed ID: 2718284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma.
    Gulyassy PF; Jarrard E; Stanfel L
    Adv Exp Med Biol; 1987; 223():55-8. PubMed ID: 3128940
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hematologic changes in chronic uremia].
    Schnurr E
    Dtsch Med Wochenschr; 1979 Nov; 104(47):1678-82. PubMed ID: 510197
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of middle molecular weight fraction in the plasma of patients with uremia using high performance liquid chromatography and thin layer chromatography].
    Kovalishin IaF; Nikolaev VG; Baran EIa; Dudar' IA; Iushko LA
    Vopr Med Khim; 1988; 34(6):23-6. PubMed ID: 3238937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations on clinico-chemical correlations in uraemic polyneuritis.
    Man NK; Cueuille G; Zingraff J; Drueke T; Jungers P; Sausse A; Billon JP; Funck-Brentano JL
    Proc Eur Dial Transplant Assoc; 1975; 11():214-21. PubMed ID: 1197256
    [No Abstract]   [Full Text] [Related]  

  • 17. Parathyroid hormone and the uremic manifestations.
    Massry SG
    Contrib Nephrol; 1980; 20():84-91. PubMed ID: 6249538
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism.
    Massry SG
    Kidney Int Suppl; 1983 Dec; 16():S204-7. PubMed ID: 6376915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of uremia: physiopathology and clinical signs.
    Bergström J
    Contrib Nephrol; 1989; 71():1-9. PubMed ID: 2680257
    [No Abstract]   [Full Text] [Related]  

  • 20. Separation from uremic body fluids and normal urine of Na+, K+-ATPase inhibitor.
    Gallice P; Monti JP; Braguer D; Durand C; Manchon H; Murisasco A; Crevat A
    Adv Exp Med Biol; 1987; 223():215-8. PubMed ID: 2833847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.